Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas

Inclusion Criteria: * Age: \< 18 years * Tumor: Progressive or recurrent low grade glioma, WHO grade 1 or 2 who have failed at least one form of 'conventional' non-surgical therapy * Histologic confirmation is required with the exception of optic pathway and brain stem gliomas. Patients are not required to have a re-operation at time of recurrence. * Patients with disseminated disease are eligible. * Children with neuro-fibromatosis and optic pathway or brainstem tumors are eligible but must have definitive radiologic or clinical evidence of progression * Patients must have evidence of measureable disease * Performance status: Karnofsky or Lansky performance status of \>50% * Organ Function: * Adequate bone marrow function (ANC\>1000/mm3, platelet count of \>75,000/mm3, and hemoglobin \> 8gm/dL) prior to starting therapy. Hemoglobin may be supported by transfusion * Adequate liver function (SGPT/ALT\<2.5 times ULN and bilirubin \< 1.5 times ULN) prior to starting therapy * Prior therapy: * May have had treatment including surgery, chemotherapy, or radiotherapy for any number of relapses prior to enrollment * Patients must have received their last fraction of radiotherapy \>12 weeks prior to starting therapy * Previous Vincristine or Vinblastine exposure is allowable. Exclusion Criteria: * No other significant medical illness that in the investigators' opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy * Any other cancer (except non-melanoma skin cancer), unless in complete remission and off of all therapy for that disease for a minimum of 3 years. * Patients of childbearing potential must not be pregnant or breast-feeding (vinorelbine is a pregnancy category D, no data on excretion in breastmilk) * Patients of childbearing or fathering potential must practice adequate contraception